We have commercial preparations well underway for anticipated expansion into the second population, a launch that will be boosted by our significant head start into the market with the KMT2A approval and physicians rapidly growing familiarity with Revuforj. To ensure that Revuforj is positioned for near term and long term success, we are laser focused on strong execution against our strategic launch imperatives they originally outlined on our Revuforj approval call in November. Each day we are focused on ensuring that we leave no appropriate patient behind, engaging all key stakeholders and delivering a best-in-class experience for patients and clinicians. Our strategy is designed to first and foremost meet the needs of patients and secondly, to build long term competitive immunity ahead of me2 [ph] products potentially entering the market.